Disease Severity at Advanced Therapy Initiation in Real-World Psoriasis Patients in the US
Author(s)
Jessica R. Probst, MPH, Teresa H. Smith, MS, Anna Swenson, MPH, Ombretta Palucci, ..
OM1, Boston, MA, USA.
OM1, Boston, MA, USA.
OBJECTIVES: A growing body of evidence suggests that early intervention with systemic therapies may improve clinical outcomes in immune-mediated diseases, however evidence is limited in Psoriasis (PsO). This study aims to describe psoriasis patients by disease severity at the time of decision to initiate advanced therapy to better characterize real-world treatment patterns.
METHODS: Methods: Data were derived from the OM1 PremiOM™ PsO dataset (OM1, Boston, MA), consisting of linked dermatology EMR data and healthcare claims on US patients with PsO. Patients were included if they initiated an advanced therapy (index date) between 1/1/2013 - 1/22/2025, had at least 1 year of baseline data available with no evidence of prior advanced therapy, and an estimated or observed percent body surface area assessment (e/BSA) at index. Patients were analyzed by categorical PsO severity at first prescription of advanced treatment.
RESULTS: 9,302 patients met the study criteria; 14% had mild (e/BSA <3), 27% had moderate (e/BSA 3-<10), and 59% had severe PsO (e/BSA ≥10) at index. A higher proportion of patients with mild & moderate PsO at index were female (58.9%, 59.4% vs 51.9%) & White (78.2%, 76.4% vs 73.0%). Greater proportions of patients with mild & moderate disease had hand/foot involvement (18.3%, 18.6% vs 15.7%), while patients with severe PsO had more upper extremity (33.4% vs 28.0%, 27.4%) and trunk involvement (32.5% vs 22.4%, 24.7%).The most common therapies initiated were PDE-4 inhibitors (36.3%), IL-23 inhibitors (22.5%), and TNFɑ inhibitors (18.4%). Use of IL-23 inhibitors increased with severity (15.7%, 18.1%, 26.1%).
CONCLUSIONS: In this analysis, most patients initiating advanced therapy had severe PsO. Patients initiating treatment with low disease severity were more likely to be female and White.
METHODS: Methods: Data were derived from the OM1 PremiOM™ PsO dataset (OM1, Boston, MA), consisting of linked dermatology EMR data and healthcare claims on US patients with PsO. Patients were included if they initiated an advanced therapy (index date) between 1/1/2013 - 1/22/2025, had at least 1 year of baseline data available with no evidence of prior advanced therapy, and an estimated or observed percent body surface area assessment (e/BSA) at index. Patients were analyzed by categorical PsO severity at first prescription of advanced treatment.
RESULTS: 9,302 patients met the study criteria; 14% had mild (e/BSA <3), 27% had moderate (e/BSA 3-<10), and 59% had severe PsO (e/BSA ≥10) at index. A higher proportion of patients with mild & moderate PsO at index were female (58.9%, 59.4% vs 51.9%) & White (78.2%, 76.4% vs 73.0%). Greater proportions of patients with mild & moderate disease had hand/foot involvement (18.3%, 18.6% vs 15.7%), while patients with severe PsO had more upper extremity (33.4% vs 28.0%, 27.4%) and trunk involvement (32.5% vs 22.4%, 24.7%).The most common therapies initiated were PDE-4 inhibitors (36.3%), IL-23 inhibitors (22.5%), and TNFɑ inhibitors (18.4%). Use of IL-23 inhibitors increased with severity (15.7%, 18.1%, 26.1%).
CONCLUSIONS: In this analysis, most patients initiating advanced therapy had severe PsO. Patients initiating treatment with low disease severity were more likely to be female and White.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD66
Topic
Clinical Outcomes, Health Service Delivery & Process of Care, Real World Data & Information Systems
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)